SecBot SecBot
SECBOTREPLAY Home › Report › AXSM

AXSM · Axsome Therapeutics adopted a formal Executive Severance and Change in…

Axsome Therapeutics, Inc. · 8-K filed Jun 9, 2026 at 17:20 ET

At the news

NEUTRALIMPACT 2/10

8-K filed Jun 9, 2026 at 17:20 ET

Axsome Therapeutics adopted a formal Executive Severance and Change in Control Plan effective June 5, 2026, covering the CEO (Tier 1), other Section 16 officers (Tier 2), and VPs+ (Tier 3). The plan provides cash severance of 18/12/6 months' base salary outside a change of control, and 24/18/9 months' salary plus target bonus, full equity acceleration, and COBRA payments upon a qualifying termination during a change of control period. This is a routine adoption of a standardized severance framework that supersedes prior individual agreements, with no departure or appointment of any officer.

  • Plan adopted June 5, 2026, approved by Compensation Committee
  • CEO (Tier 1) gets 18 months base salary severance outside CIC, 24 months plus target bonus and full equity vesting during CIC period
  • Other Section 16 officers (Tier 2) get 12 months base salary outside CIC, 18 months plus target bonus and full equity vesting during CIC period
  • VPs+ (Tier 3) get 6 months base salary outside CIC, 9 months plus target bonus and full equity vesting during CIC period

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access